Advertisement

Endocrine Disorders

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Chapter
  • 1.8k Downloads

Abstract

With ageing, few morphological changes have been reported in the pancreas which include a degree of atrophy, fatty infiltration and fibrosis and the presence of amyloid material and lipofuscin granules. The age-related decline in glucose handling seems to result from insulin resistance rather than an impairment of insulin secretion. Possible explanations for this age-related insulin resistance include various factors such as fat mass, fat distribution, dietary composition, physical activity and capacity of glucose uptake. Long-standing diabetes is associated with damage and dysfunction of large (macrovascular) and small (microvascular) blood vessels resulting in damage to various organs. Microvascular dysfunction occurs early in diabetes and parallels progression of neural dysfunction. With ageing, the number and size of thyroid follicles and the colloid content decrease. There is lymphocytic infiltration and fibrosis of the connective tissue on histological examination. Serum levels of thyroid hormones change little with age. TSH changes during healthy ageing are equivocal but typically remains normal except for a mild decrease in extreme senescence. There is an elevation of thyroid antibodies with ageing, but this increase appears to be related to age-associated diseases rather than to ageing per se. In the elderly thyroid function tests may be influenced by illness, malnutrition and medication. T4 production declines with advancing age, but serum T4 (total and free) concentrations remain unchanged. The parathyroid hormone level increases with age, but the calcitonin level seems to decrease with age. Patients with primary hyperparathyroidism (PHPT) have an increased bone turnover and decreased BMD associated with low vitamin D states and high plasma 1,25(OH) D.

Keywords

Age-related changes Age-related insulin resistance Thyroid follicles Thyrotropic-stimulating hormone Parathyroid hormone 

References

Anatomical and Physiological Changes with Ageing-Endocrine System

  1. 1.
    Glaser J, Stienecker K. Pancreas and aging: a study using ultrasonography. Gerontology. 2000;46(2):93–6 (abstract).PubMedCrossRefGoogle Scholar
  2. 2.
    Elahi D, Muller DC. Carbohydrate metabolism in the elderly. Eur J Clin Nutr. 2000;54:S112–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Dl B, Taylor R. Review: deterioration of glucose tolerance with age: the role of insulin resistance. Age Ageing. 1991;20:221–5.CrossRefGoogle Scholar
  4. 4.
    Reaven GM, Chen N, Hollenbeck C, Chen YDI. Effect of age on glucose tolerance and glucose uptake in healthy individuals. J Am Geriatr Soc. 1989;37:735–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Gong Z, Muzumdar RH. Pancreatic function, Type 2 diabetes and metabolism and aging. Int J Endocrinol. 2012;(2012). Aricle ID:320482, 13 pages. http://dx.doi.org/10.1155/2012/320482.
  6. 6.
    Perry 3rd HM. The endocrinology of aging. Clin Chem. 1999;45:1369–76.PubMedGoogle Scholar
  7. 7.
    Davidson M. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism. 1979;28:688–705.PubMedCrossRefGoogle Scholar
  8. 8.
    Maneatis T, Condie R, Reaven G. Effect of age on plasma glucose and insulin responses to a test mixed meal. J Am Geriatr Soc. 1982;30:178–82.PubMedCrossRefGoogle Scholar
  9. 9.
    Barbieri M, Rizzo MR, Manzella D, Paolisso G. Age-related insulin resistance: is it obligatory finding? The lesson from healthy centenarians. Diabetes Metab Res Rev. 2001;17:19–26.PubMedCrossRefGoogle Scholar
  10. 10.
    DeFronzo R. Glucose tolerance and aging. Diabetes Care. 1981;4:493–501.PubMedCrossRefGoogle Scholar
  11. 11.
    Fink RI, Wallace P, Olefsky JM. Effects of aging on glucose-mediated glucose disposal and glucose transport. J Clin Invest. 1986;77:2034–41.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Peeters RP. Thyroid hormones and aging. Hormones. 2008;7(1):28–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Herrmann J, Heinen E, Kroll HJ, Rudorff RH, Kruskemper HL. Thyroid function and thyroid hormone metabolism in the elderly people. Low T3-syndrome in old age? Klin Wochenschr. 1981;59:315–23.PubMedCrossRefGoogle Scholar
  14. 14.
    Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr Rev. 1995;16:686–715.PubMedCrossRefGoogle Scholar
  15. 15.
    Begin ME, Langlow MF, Lorrain D, Cunnarie SC. Thyroid function and cognition during ageing. Curr Gerontol Geriatr Res. 2008 (Article ID474868). http://dx.doi.org/10.1155/2008/474868.
  16. 16.
    Shams N, Hamad S. Case: report: hypothyroidism in the elderly. Mid East J Age Ageing. 2007;4. website: http://www.me-jaa.com/me-jaal1June07/hypothyroidism.htm.
  17. 17.
    Garber J. Who is at risk for thyroid disease? website: http://www.thyroidawareness.com/assessmentresource.html.
  18. 18.
    Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Wickham survey. Clin Endorinol (Oxf). 1977;7:481–93.CrossRefGoogle Scholar
  19. 19.
    Hijmans W, Radl J, Bottazzo GF, Doniach D. Autoantibodies in highly aged humans. Mech Ageing Dev. 1984;26:83–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Need AG, O’Loughlin PD, Morris HA, Horowitz M, Nordin BE. The effects of age and other variables on serum parathyroid hormone in postmenopausal women attending an osteoporosis center. J Clin Endocrinol Metab. 2004;89(4):1646–9 (abstract).PubMedCrossRefGoogle Scholar
  21. 21.
    Bilezikian JP, Silverberg ST. Parathyroid hormone: does it have a role in the pathogenesis of osteoporosis? Clin Lab Med. 2000;20:559–67.PubMedGoogle Scholar
  22. 22.
    Alaami O, Fang TD, Song HM, Nacamuli RP. Physiological features of aging persons. Arch Surg. 2003;138:1068–976.CrossRefGoogle Scholar

Diabetes Mellitus in the Elderly

  1. 23.
    Khinvasara LK. Diabetes in the elderly. Diabetes Today 2004;(3):5.Google Scholar
  2. 24.
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414–31.PubMedCrossRefGoogle Scholar
  3. 25.
    Gregg EW, Mangione CM, Cauley JA, Thompson TJ, Schawartz AV, Ensrud KE, et al. Diabetes and incidence of functional disability in older women. Diabetes Care. 2002;23:1272–7.CrossRefGoogle Scholar
  4. 26.
    Harris MI, Hadden WC, Knowler WC, Bennett PH. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389–401.PubMedGoogle Scholar
  5. 27.
    Better Health Channel. Diabetic retinopathy. State Govt of Victoria, Melbourne; 2007.Google Scholar
  6. 28.
    Rockwood K, Awalt E, Macknight C, McDowell I. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian Study of Health and Aging. CMAJ. 2000;162(6):769–72 (abstract).PubMedCentralPubMedGoogle Scholar
  7. 29.
    Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. In: Harris MI, editor. Diabetes in America. 2nd ed. NIH Pubication No 95–1468. National Institute of Health, National Institue of Diabetes and Digestive Diseases, Bethesda MO,1995, p. 47–67.Google Scholar
  8. 30.
    Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation. Beyond insulin and glucagon. Diabetes Spectr. 2004;17(3):183–90.CrossRefGoogle Scholar
  9. 31.
    Perry 3rd HM. The endocrinology of aging. Clin Chem. 1999;45:1369–76.PubMedGoogle Scholar
  10. 32.
    Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? Diab Metab. 2005;31(spec No2):5S27–34.Google Scholar
  11. 33.
    Ryan AS. Insulin resistance with ageing: effects of diet and exercise. Sports Med. 2000;30(5):327–46.Google Scholar
  12. 34.
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:S5–10.CrossRefGoogle Scholar
  13. 35.
    Defranzo RB. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.CrossRefGoogle Scholar
  14. 36.
    Mahler RJ, Adler ML. Type 2 diabetes mellitus: update in the diagnosis, pathophysiology and treatment. J Clin Endocrinol Metab. 1999;84(4):1164–71.Google Scholar
  15. 37.
    Yarlow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1969;39:1159–62.Google Scholar
  16. 38.
    Meneily GS. Pathophysiology of type 2 diabetes in the elderly. Clin Geriatr Med. 1999;15:239–53.Google Scholar
  17. 39.
    Chau D, Edelman SV. Clinical management of diabetes in the elderly. Clin Diabetes. 2001;19(4):172–5.CrossRefGoogle Scholar
  18. 40.
    Gleichman H, Zorcher B, Grenlich B, Gries FA, Henricks HR, Betrams J, et al. Correlation of islet cell antibodies and HKA-DR phenotypes in diabetes mellitus in adults. Diabetologia. 1984;27:90–2.CrossRefGoogle Scholar
  19. 41.
    Yared Z, Chiasson JL. Ketoacidosis and the hyperosmolar hypeglycaemic state in adult diabetic patients. Diagnosis and treatment. Minerva Med. 2003;94(6):409–18.PubMedGoogle Scholar
  20. 42.
    Magee MF, Bhatt BA. Management of decompensated diabetes: diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome. Crit Care Clin. 2001;17:75–106.PubMedCrossRefGoogle Scholar
  21. 43.
    Gouni-Berthold I, Krone W. Diabetic ketoacidosis and hyperosmolar hyperglycaemic state. Med Klin (Munich). 2006;101:100–5.Google Scholar
  22. 44.
    Clayton W, Elasy TA, Tom A. A review of the pathophysiology, classification and treatment of foot ulcers in diabetic patients. Clin Diabetes. 2009;27(2):52–8.CrossRefGoogle Scholar
  23. 45.
    Kuroki T, Isshiki K, King G. Oxidative stress: the lead or supporting actor in the pathogenesis of diabetic complications. J Am Soc Nephrol. 2003;14:S216–20.PubMedCrossRefGoogle Scholar
  24. 46.
    Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC an inhibitor. Science. 1996;72:728–31.CrossRefGoogle Scholar
  25. 47.
    Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 2000;13:2329–37.Google Scholar
  26. 48.
    King KD, Jones JD, Warthen J. Microvascular and macrovascular complications in diabetes mellitus. Amer J Pharm Edu. 2005;69(5):Article 87.Google Scholar
  27. 49.
    Kikkawa R. Chronic complications in diabetes mellitus. Br J Nutr. 2000;84 Suppl 2:S183–5.PubMedCrossRefGoogle Scholar
  28. 50.
    Nishio Y, Kashiwagi A, Taki H, Shinozaki K, Maeno Y, Kojima H, et al. Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes. 2000;47:1318–25.CrossRefGoogle Scholar
  29. 51.
    Vinik AI. Diagnosis and management of diabetic neuropathy. Clin Geriatr Med. 1999;15:293–320.PubMedGoogle Scholar
  30. 52.
    Odenthal U, Haehn S, Tunggal P, Merke B, Schomburg D, Frie C, et al. Molecular analysis of laminin N-terminal mediating self-interactions. J Biol Chem. 2006;279(43):44504–12 (abstract).CrossRefGoogle Scholar
  31. 53.
    Young MJ, Boulton AJM, Macleod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in United Kingdom hospital clinic population. Diabetologia. 1993;36:150–4.PubMedCrossRefGoogle Scholar
  32. 54.
    Tesfaye S. Epidemiology and etiology of diabetic peripheral neuropathy. Adv Stud Med. 2004;4(10G):S1014–21.Google Scholar
  33. 55.
    Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic cardiovascular autonomic neuropathy Multicentre Group. J Diabetes Complications. 1992;6(1):49–59 (abstract).PubMedCrossRefGoogle Scholar
  34. 56.
    Vinik AL, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia. 2000;43(8):957–73 (abstract).PubMedCrossRefGoogle Scholar

Thyroid Disease in the Older Patient

  1. 57.
    Empson M, Flood V, Ma G, Eastman CJ, Mitchell P. Prevalence of thyroid disease in older Australian population. Intern Med J. 2007;37:448–56.PubMedCrossRefGoogle Scholar
  2. 58.
    Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Wichkam survey. Clin Endocrinol (Oxf). 1977;7:481–93.CrossRefGoogle Scholar
  3. 59.
    Canario GJ, Manowitz NR, Maypor G, Ridgway EC. The Colorado thyroid disease: prevalence study. Arch Intern Med. 2000;110:526–30.CrossRefGoogle Scholar
  4. 60.
    Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142–54.PubMedCrossRefGoogle Scholar
  5. 61.
    Bremner AP, Feddema P, Leedman PJ, Brown SJ, Beilby JP, Lim EM, et al. Age-related changes in thyroid function: a longitudinal study of a community –based cohort. J Clin Endocrinol Metab. 2012;97:1554–62.PubMedCrossRefGoogle Scholar
  6. 62.
    Klein I, Ojamma K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501–9.PubMedCrossRefGoogle Scholar
  7. 63.
    Kanaya AM, Harris F, Volpato S, Perez-Stable EJ, Harris T, Bauer DC. Association between thyroid dysfunction and total cholesterol level in older bi-racial population, the health, aging and body composition study. Arch Intern Med. 2002;162:773–9.PubMedCrossRefGoogle Scholar
  8. 64.
    Helfand M, Crapo IM. Screening for thyroid disorder. Ann Intern Med. 1990;112:840–9.PubMedCrossRefGoogle Scholar
  9. 65.
    Brent GA, Mestman JH. Diagnosis of the major step involved in thyroid hormone synthesis and secretion. Totuwa: Humana Press; 1996.Google Scholar
  10. 66.
    Nakamura M, Ohtaki S. Molecular mechanism of thyroid hormone synthesis. Nihon Rinsho. 1994;52(4):857–63 (abstract).PubMedGoogle Scholar
  11. 67.
    Islam S. Thyroid gland. Norm Physiol. http://www.pathologyoutlines.com/topic/thyroidphysiology.html. Retrieved 15 Apr 2014.
  12. 68.
    Bonert V, Friedman TC. Chapter 65: The thyroid gland. In: Andreoli TE, editor. Cecil essentials of medicine. 5th ed. Philadelphia PA:WBaunders; 2001. pp. 543–604.Google Scholar
  13. 69.
    Roy G, Mugesh G. Thyroid hormone synthesis and anti-thyroid drugs: a bioinorganic chemistry approach. J Chem Sci. 2006;118:619–28.CrossRefGoogle Scholar
  14. 70.
    Hennemann G, Visser TJ. Chapter 4. Thyroid hormone synthesis, plasma membrane transport and metabolism. In: Weetman AP, Grossman, editors. Pharmatherapeutics of the thyroid gland, Handbook of experimental pharmacology, vol. 128. Berlin: Springer; 1997. p. 75–7.Google Scholar
  15. 71.
    Chiovato L, Mariotti S, Pinchera A. Thyroid diseases in the elderly. Baillieres Clin Endocrinol Metab. 1997;11:251–70.PubMedCrossRefGoogle Scholar
  16. 72.
    Hermann J, Heinen E, Kroll HJ, Rudorff KH, Kruskemper HL. Thyroid function and thyroid hormone metabolism in elderly people. Low T3 –syndrome in old age? Klin Wochenchr. 1981;59:315–23.CrossRefGoogle Scholar
  17. 73.
    Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr Rev. 1995;16:686–715.PubMedCrossRefGoogle Scholar
  18. 74.
    Wilson GR, Curry RW. Subclinical thyroid disease. Am Fam Physician. 2005;72(8):1517–24 (abstract).PubMedGoogle Scholar
  19. 75.
    Samuels MH. Subclinical thyroid disease in the elderly. Thyroid. 1998;8(9):803–13.PubMedCrossRefGoogle Scholar
  20. 76.
    Faggiono A, Del Prete M, Marciello V, Marotta V, Ramundo V, Colao A. Thyroid diseases in the elderly. Minerva Endocrinol. 2011;36:211–31.Google Scholar
  21. 77.
    Rukhman N, Silverberg A. Thyroid cancer in men. Aging Male. 2011;14:91–8.PubMedCrossRefGoogle Scholar
  22. 78.
    Hollowel JG, Staenling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T4, and thyroid antibodies in the United States Population (1988–1994) National Health and Nutrition Examination Survey (NHANES-III). J Clin Endocrinol Metab. 2002;87:481–91.Google Scholar
  23. 79.
    Roti M, Montermini G, Robuschi G, Gardin IE, Salvo D, Gionet M, et al. Prevalence of hypothyroidism, Hashimoto’s thyroiditis in two elderly populations with different dietary iodine intake. In: Pinchera A, Ongbar SH, McKenzie J, Fenzis GF, editors. Thyroid Autoimmunity New York NY: Plenum Press; 1987. pp. 555–557.Google Scholar
  24. 80.
    Diez JJ. Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J Gerontol A Biol Sci Med Sci. 2002;57:M315–20.PubMedCrossRefGoogle Scholar
  25. 81.
    Almandoz JP, Gharib H. Hypothyroidism: etiology, diagnosis and management. Med Clin North Am. 2012;96:203–21.PubMedCrossRefGoogle Scholar
  26. 82.
    Laurberg P, Andersen S, Bulow Pedersen I, Carle A. Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging. 2005;22(1):23–38 (abstract).PubMedCrossRefGoogle Scholar
  27. 83.
    Haughen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793–800.Google Scholar
  28. 84.
    Mestman J. Disorders of the thyroid gland. Glob Libr Women’s Med. (ISSN: 1756–2228) 2008. doi:  10.3843/GLOWM.10308.
  29. 85.
    Swain M, Swain T, Mohanty B. Autoimmune disorders-an update. Indian J Clin Biochem. 2005;20(1):9–17.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 86.
    Marcocci C, Chiovito L. Thyroid directed antibodies. In: Braverman LE, Utiger RD, editors. The thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lipincott William and Wilkins; 2000. p. 414–31.Google Scholar
  31. 87.
    Ichikawa K, Kaneko T, Suzuki S, Komatsu M, Yamauci K, Aizawa T, et al. Aging and Hashimoto’s thyroiditis. Nihon Ronen Igakkai Zasshi. 1998;35(10):771–6 (abstract).PubMedCrossRefGoogle Scholar
  32. 88.
    Lerch M, Meier C, Staub JJ. Is there a need for treatment in subclinical hypo-hyperthyroidism? Ther Umsch. 1999;56(7):369–73 (abstract).PubMedCrossRefGoogle Scholar
  33. 89.
    Krysiak R, Okopien B, Herman Z. Pol Merkur Lekarski. 2006;31(126):573–8. (abstract).Google Scholar
  34. 90.
    Jayme JJ, Ladenson PW. Subclinical thyroid dysfunction in the elderly. Trends Endocrinol Metab. 1994;5(2):79–82.PubMedCrossRefGoogle Scholar
  35. 91.
    Jameson JL, Weetman AP. Disorders of the thyroid gland. In: Longo D, Fauci A, Kasper D, Haiuser S, Jameson J, Loscalzo J, editors. Harrisons principles of internal medicine. 18th ed. New York: McGraw –Hill; 2012. p. 2911–39.Google Scholar
  36. 92.
    Goldenberg LMC. Thyroid disease in late life. Thyroid Foundation of Canada. http://www.thyroid.ca/e4g.php. Retrieved 30 July 2013.
  37. 93.
    de Luise MA. Thyroid disease in the elderly. J Pharm Pract Res. 2003;33:228–30.Google Scholar
  38. 94.
    Diez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology. 2003;49:316–23. 39.PubMedCrossRefGoogle Scholar
  39. 95.
    Parle JV, Franklyn JA, Cross KW, Jones SR, Shepperd MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of under treatment or over treatment. Br J Gen Pract. 1993;43:107–9.PubMedCentralPubMedGoogle Scholar
  40. 96.
    Sawin TC, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.PubMedCrossRefGoogle Scholar
  41. 97.
    Muddle AA, Reijinders FJL, Nieuwenhuijzen Krusman AC. Peripheral bone density in women with untreated multinodular goiter. Clin Endocrinol. 1992;37:35–9.CrossRefGoogle Scholar
  42. 98.
    Santos Palacios S, Pascual-Corrales E, Galofore JC. Management of subclinical hyperthyroidism. Int J Endocrinol Metab. 2012;10(2):490–6 (abstract).PubMedCentralPubMedCrossRefGoogle Scholar
  43. 99.
    Givelli ME, Cesara D, Rubello R, Mazzarotto R, Saladini G, Busnardo B. Differentiated thyroid cancer in the elderly, disease outcome, therapeutic approach and long-term results in a group of 314 patients. J Endocrinol Invest. 1999;22:45–6.Google Scholar
  44. 100.
    Lin JD, Chao TC, Chen ST, Weng HF, Lin KD. Characteristics of thyroid carcinomas in ageing patients. Eur J Clin Invest. 2000;30:147–53.PubMedCrossRefGoogle Scholar
  45. 101.
    Gesing A, Lewinski A, Karbownik-Lewinska M. The thyroid gland and the process of aging: what is new? Thyroid Res. 2012;5:16. doi: 10.1186/1756-6614-5-16.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 102.
    Ito Y, Higashiyama T, Takamura Y, et al. Risk factors for recurrence to lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;312:2085–91.CrossRefGoogle Scholar
  47. 103.
    Liebner DA, Shah MH. Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2011;2(5):173–95.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 104.
    Brzezianska E, Pastuzak-Lewandoska D. A minireview: the role of MAPK/ERK and P13K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci (Landmark Ed). 2011;16:422–39.CrossRefGoogle Scholar
  49. 105.
    Health Encyclopedia-Diseases and Conditions. Thyroid cancer. http://www.healthscout.com/ency/68/469/main.html. Retrieved 21 July 2009.
  50. 106.
  51. 107.
    University of Virginia Health System. Survival Statistics, AJCC Cancer Strategies Manual. 7th ed. http://www.cancer.orf/cancer/thyroidcancer/detailedguide/thyroid_cancer.survival. Retrieved 31 July 2013.

Hyperparathyroidism

  1. 108.
    Deshmukh RG, Alsagoff SA, Krishnan S, Dhillon KS, Khir ASM. Primary hyperparathyroidism presenting with pathological fractures. J R Coll Surg Edinb. 1998;43(6):424–7.PubMedGoogle Scholar
  2. 109.
    Yu N, Dinnan PT, Murphy J, Leese GP. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002;17 Suppl 2:N18–23 (abstract).Google Scholar
  3. 110.
    Bolland MJ, Grey AB, Gamble GD, Reid LR. Association between primary hyperparathyroidism and increased body weight: a meta analysis. J Clin Endocrinol Metab. 2004;90(3):1525–30.PubMedCrossRefGoogle Scholar
  4. 111.
    Adami S, Marcocci C, Gatt D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002;17 suppl 2:N18–23 (abstract).PubMedGoogle Scholar
  5. 112.
    Wermier RA, Khosle S, Atkinson EG, Achenbach SJ, Oberg AL, Grant CS, et al. The rise and fall of primary hyperparathyroidism: population based study in Rochester, Minnesota. Ann Intern Med. 1997;126(6):433–40 (abstract).CrossRefGoogle Scholar
  6. 113.
    Brown EM. The pathophysiology of primary hyperparathyroidism. J Bone Miner Res. 2002;17(Suppl 2):N24–9 (abstract).Google Scholar
  7. 114.
    Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des. 2002;8(23):2077–87 (abstract).PubMedCrossRefGoogle Scholar
  8. 115.
    Cetani F, Picone A, Cerrai P, Vignali E, Borsans S, Pardi E, et al. Parathyroid expression of calcium sensory receptor protein and in vivo parathyroid hormone-Ca (2+) set-point in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85(2):4789–94.PubMedGoogle Scholar
  9. 116.
    Johnson NA, Tublin ME, Ogilivie JB. Parathyroid injury. Technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am J Roentgenol. 2007;188:1706–15.PubMedCrossRefGoogle Scholar
  10. 117.
    Ruda JM, Hollenbeak CS, Jr S. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995–2013. Otolaryngol Head Neck Surg. 2005;132:359–72.PubMedCrossRefGoogle Scholar
  11. 118.
    Carnevale V, Romagnoli E, Pipino M, Scillitane A, D’Erasmo E, Miaisola S, et al. Primary hyperparathyroidism. Clin Ther. 2005;156(5):211–26 (abstract).Google Scholar
  12. 119.
    Hellman P, Carling T, Rask L, Akerstrom G. Pathophysiology of primary hyperparathyroidism. Histol Histopathol. 2000;15(2):619–27 (abstract).PubMedGoogle Scholar
  13. 120.
    Mosgaard B, Chrostensen SE, Vestergaard P, Heickendorff HL, Christiansen P, Mosekilde L, et al. Vitamin D mobility and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2006;68(5):707–15 (abstract).CrossRefGoogle Scholar
  14. 121.
    Mosekilk L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69(1):1–19 (abstract).CrossRefGoogle Scholar
  15. 122.
    Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyroidism. Ther Adv Musculoskelet Dis. 2012;4(5):357–68 (abstract).PubMedCentralPubMedCrossRefGoogle Scholar
  16. 123.
    Pitt SC, Sippel Rebecca RS, Chen H. Secondary and tertiary hyperparathyroidism, State of the Art Surgical Management. Surg Clin North Am. 2009;89(5):1227–39.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 124.
    Dabbagh S. Renal osteodystrophy. Curr Opin Pediatr. 1998;10(2):190–6 (abstract).PubMedCrossRefGoogle Scholar
  18. 125.
    Pitt SC, Sippi RS, Chen H. Secondary and tertiary hyperparathyroidism: State of the Art Surgical Management. Surg Clin North Am. 2009;89(5):1227–39.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 126.
    Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–21.PubMedCrossRefGoogle Scholar
  20. 127.
    Memmos D, Williams G, Eastwood J, Gordon EM, Cochrane CL, Gower PE, et al. The role of parathyroidectomy in the management of hyperparathyroidism in patients on maintenance haemodialysis and after renal transplantation. Nephron. 1982;30:143–8.PubMedCrossRefGoogle Scholar
  21. 128.
    Bilezkian JP, Khan I, Potts JT, Brandi ML, Clarke BL, Shoback D, et al. Hyperparathyroidism in the adult: epidemiology, diagnosis, pathophysiology. Target-organ involvement. Treatment and challenges for future research. J Bone Miner Res. 2011;26(10):2317–37.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 2
  • Gary Cheuk
    • 3
  1. 1.Sydney Medical School (Westmead)The University of SydneyNorth RocksAustralia
  2. 2.Norwest Specialist Medical GroupBella VistaAustralia
  3. 3.Blacktown-Mt Druitt HospitalBlacktownAustralia

Personalised recommendations